WEKO3
アイテム
{"_buckets": {"deposit": "e5b80531-0703-4831-ac78-32bf2f732b84"}, "_deposit": {"created_by": 1, "id": "49410", "owners": [1], "pid": {"revision_id": 0, "type": "depid", "value": "49410"}, "status": "published"}, "_oai": {"id": "oai:repo.qst.go.jp:00049410", "sets": ["1"]}, "author_link": ["790730", "790731", "790727", "790735", "790733", "790734", "790732", "790729", "790738", "790728", "790739", "790737", "790736"], "item_8_biblio_info_7": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "2", "bibliographicPageEnd": "741", "bibliographicPageStart": "734", "bibliographicVolumeNumber": "110", "bibliographic_titles": [{"bibliographic_title": "Cancer Science"}]}]}, "item_8_description_5": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Abstract\nEfficacy and safety of carbon-ion radiotherapy (CIRT) for locally advanced non-small-cell lung cancer (LA-NSCLC) remain unclear. We reported the clinical outcomes of CIRT for LA-NSCLC. Data of 141 eligible patients who received CIRT between 1995 and 2015 were retrospectively analyzed. Local control (LC), locoregional control (LRC), progression-free survival (PFS), and OS were calculated using Kaplan-Meier method. The median age was 75.0 years. Overall, 21, (14.9%), 57 (40.4%), 43 (30.5%), and 20 (14.2%) patients had T1, T2, T3, and T4 disease, respectively. Moreover, 51 (36.2%), 45 (31.9%), 40 (28.4%), and 5 (3.5%) patients had N0, N1, N2, and N3 disease, respectively. Furthermore, 34 (24.1%), 42 (29.8%), 45 (31.9%), and 20 (14.2%) patients had stages IIA, IIB, IIIA, and ΙΙΙB disease, respectively. Overall, 62 (44.0%), 60 (42.6%), 8 (5.7%), and 11 (7.8%) patients had adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others, respectively. The median dose was 72.0 Gy (relative biological effectiveness). No patient received concurrent chemotherapy. Median follow-up periods were 29.3 (1.6-207.7) and 40.0 (10.7-207.7) months for all patients and survivors, respectively. Two-year LC, PFS, and OS rates were 80.3%, 40.2%, and 58.7%, respectively. Overall, 1 (0.7%), 5 (3.5%), and 1 (0.7%) patient developed Grades 4 (mediastinal hemorrhage), 3 (radiation pneumonitis), and 3 (bronchial fistula) toxicities, respectively. Multivariate analysis showed adenocarcinoma and N2/3 classification as significant poor prognosticators of PFS. CIRT is an effective treatment with acceptable toxicity for LA-NSCLC, especially for elderly patients or patients with severe comorbidities who cannot be treated with surgery or chemoradiotherapy. This article is protected by copyright. All rights reserved.", "subitem_description_type": "Abstract"}]}, "item_8_publisher_8": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Wiley"}]}, "item_8_relation_13": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "30467928 ", "subitem_relation_type_select": "PMID"}}]}, "item_8_relation_14": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1111/cas.13890", "subitem_relation_type_select": "DOI"}}]}, "item_8_relation_17": {"attribute_name": "関連サイト", "attribute_value_mlt": [{"subitem_relation_type_id": {"subitem_relation_type_id_text": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361552/", "subitem_relation_type_select": "URI"}}]}, "item_8_source_id_9": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "1347-9032", "subitem_source_identifier_type": "ISSN"}]}, "item_access_right": {"attribute_name": "アクセス権", "attribute_value_mlt": [{"subitem_access_right": "metadata only access", "subitem_access_right_uri": "http://purl.org/coar/access_right/c_14cb"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Hayashi, Kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "790727", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamamoto, Naoyoshi"}], "nameIdentifiers": [{"nameIdentifier": "790728", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakajima, Mio"}], "nameIdentifiers": [{"nameIdentifier": "790729", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nomoto, Akihiro"}], "nameIdentifiers": [{"nameIdentifier": "790730", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "790731", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Ogawa , kazuhiko"}], "nameIdentifiers": [{"nameIdentifier": "790732", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamada, Tadashi"}], "nameIdentifiers": [{"nameIdentifier": "790733", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hayashi, Kazuhiko", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "790734", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Yamamoto, Naoyoshi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "790735", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nakajima, Mio", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "790736", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Nomoto, Akihiro", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "790737", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Tsuji, Hiroshi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "790738", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kamada, Tadashi", "creatorNameLang": "en"}], "nameIdentifiers": [{"nameIdentifier": "790739", "nameIdentifierScheme": "WEKO"}]}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": " Clinical outcomes of carbon‐ion radiotherapy for locally advanced non‐small‐cell lung cancer", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": " Clinical outcomes of carbon‐ion radiotherapy for locally advanced non‐small‐cell lung cancer"}]}, "item_type_id": "8", "owner": "1", "path": ["1"], "permalink_uri": "https://repo.qst.go.jp/records/49410", "pubdate": {"attribute_name": "公開日", "attribute_value": "2019-01-08"}, "publish_date": "2019-01-08", "publish_status": "0", "recid": "49410", "relation": {}, "relation_version_is_last": true, "title": [" Clinical outcomes of carbon‐ion radiotherapy for locally advanced non‐small‐cell lung cancer"], "weko_shared_id": -1}
Clinical outcomes of carbon‐ion radiotherapy for locally advanced non‐small‐cell lung cancer
https://repo.qst.go.jp/records/49410
https://repo.qst.go.jp/records/494101a820bce-1ab3-48dc-bfec-5f3758a98f7e
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2019-01-08 | |||||
タイトル | ||||||
タイトル | Clinical outcomes of carbon‐ion radiotherapy for locally advanced non‐small‐cell lung cancer | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
アクセス権 | ||||||
アクセス権 | metadata only access | |||||
アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
著者 |
Hayashi, Kazuhiko
× Hayashi, Kazuhiko× Yamamoto, Naoyoshi× Nakajima, Mio× Nomoto, Akihiro× Tsuji, Hiroshi× Ogawa , kazuhiko× Kamada, Tadashi× Hayashi, Kazuhiko× Yamamoto, Naoyoshi× Nakajima, Mio× Nomoto, Akihiro× Tsuji, Hiroshi× Kamada, Tadashi |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Abstract Efficacy and safety of carbon-ion radiotherapy (CIRT) for locally advanced non-small-cell lung cancer (LA-NSCLC) remain unclear. We reported the clinical outcomes of CIRT for LA-NSCLC. Data of 141 eligible patients who received CIRT between 1995 and 2015 were retrospectively analyzed. Local control (LC), locoregional control (LRC), progression-free survival (PFS), and OS were calculated using Kaplan-Meier method. The median age was 75.0 years. Overall, 21, (14.9%), 57 (40.4%), 43 (30.5%), and 20 (14.2%) patients had T1, T2, T3, and T4 disease, respectively. Moreover, 51 (36.2%), 45 (31.9%), 40 (28.4%), and 5 (3.5%) patients had N0, N1, N2, and N3 disease, respectively. Furthermore, 34 (24.1%), 42 (29.8%), 45 (31.9%), and 20 (14.2%) patients had stages IIA, IIB, IIIA, and ΙΙΙB disease, respectively. Overall, 62 (44.0%), 60 (42.6%), 8 (5.7%), and 11 (7.8%) patients had adenocarcinoma, squamous cell carcinoma, large cell carcinoma, and others, respectively. The median dose was 72.0 Gy (relative biological effectiveness). No patient received concurrent chemotherapy. Median follow-up periods were 29.3 (1.6-207.7) and 40.0 (10.7-207.7) months for all patients and survivors, respectively. Two-year LC, PFS, and OS rates were 80.3%, 40.2%, and 58.7%, respectively. Overall, 1 (0.7%), 5 (3.5%), and 1 (0.7%) patient developed Grades 4 (mediastinal hemorrhage), 3 (radiation pneumonitis), and 3 (bronchial fistula) toxicities, respectively. Multivariate analysis showed adenocarcinoma and N2/3 classification as significant poor prognosticators of PFS. CIRT is an effective treatment with acceptable toxicity for LA-NSCLC, especially for elderly patients or patients with severe comorbidities who cannot be treated with surgery or chemoradiotherapy. This article is protected by copyright. All rights reserved. |
|||||
書誌情報 |
Cancer Science 巻 110, 号 2, p. 734-741, 発行日 2018-11 |
|||||
出版者 | ||||||
出版者 | Wiley | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 1347-9032 | |||||
PubMed番号 | ||||||
識別子タイプ | PMID | |||||
関連識別子 | 30467928 | |||||
DOI | ||||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1111/cas.13890 | |||||
関連サイト | ||||||
識別子タイプ | URI | |||||
関連識別子 | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6361552/ |